Treatment-naïve SMA patients with two SMN2 copies exhibited significantly higher median serum NfL levels compared to both patients with more than two copies (p < 0.001) and age-matched controls (p = 0.010), with levels declining over the course of treatment [44]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.